ArticleApplied biochemistry and biotechnology2026
Structural Insights and Bioactivity Correlations of Heteroleptic Zn(II)/Cd(II) Complexes: Experimental Characterization, Theoretical Modelling, and Evaluation of Antimicrobial, Anticancer, and Lipase Inhibitory Potentials.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Driven by the critical need for new therapeutic agents, and building upon recognized biological relevance of hydroxamic acids, our rationale posits that integrating distinct ligands can precisely modulate a metal complex’s properties to achieve targeted biological activity. Two new mixed ligand complexes, [ZnCl(L)(1,10-phen)] (1) and [Cd(L)(1,10-phen)].H2O (2) {where, L = 1-naphthaleneacetohydroxamate (1-NaphAcH, C11H9CONHO) and 1,10-phen = 1,10-phenanthroline (C12H8N2)} has been synthesized by reacting ZnCl2 and CdCl2 (anhydrous) with ligand potassium 1-naphthaleneacetohydroxamate (C11H9CONHOK) (L) as primary ligand and 1,10-phenanthroline as secondary ligand. Complexes were characterized by physicochemical, spectroscopic (FTIR, 1H, 13C NMR, UV-Visible), Mass, Thermogravimetric analysis (TGA), Cyclic Voltammetry (CV) and theoretical (DFT) affirmed their distorted square pyramidal geometries and elucidated their electronic structure, revealing enhanced stability. Critically, these complexes demonstrated significant broad-spectrum antibacterial efficacy, comparable to azithromycin, against bacterial strains S. aureus, S. typhi, S. flexneri, and P. aeruginosa. Furthermore, both complexes exhibited potent cytotoxicity against L20B as well as Rhabdomyosarcoma (RD) cancer cells and IC50 values were determined substantiated by in-silico DNA binding studies elucidating probable mechanism of action. The complexes were evaluated for their in-vitro inhibitory activity against Amano Lipase PS enzyme and demonstrated efficient lipase inhibition. The stability of coordination complexes was evaluated in biological media using UV-visible spectrophotometry pertinent to their antibacterial, anticancer, and lipase enzyme inhibition activities. Molecular docking simulations corroborated these in vitro findings, demonstrating efficient docking scores. Furthermore, Normal Mode Analysis (NMA) revealed a pronounced metal-dependent modulation of protein dynamics, wherein coordination to Zn(II) and Cd(II) progressively suppresses low-frequency collective motions critical for biological function. Notably, the Cd(II) complex induces the strongest conformational stabilization and residue coupling, providing a mechanistic basis for its enhanced antibacterial activity. These findings underscore the profound potential of rational mixed-ligand design to transform metal ions into versatile, highly active biological agents for addressing pressing challenges in antimicrobial resistance, cancer therapy and lipase inhibition.
Indexed as
Identifiers
41874818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.